Phase 3 N=103 ZS Ph2/3 Dose-response Study in Japan
Hyperkalemia
Primary: Exponential Rate of Change in Serum Potassium (S-K) Values During the Initial 48 Hours of Study Drug Treatment — -0.00273; -0.00508; -0.00012 log (mmol/L) / hour…
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects
Thrombosis
Primary: The Number of Subjects With Treatment-related Adverse Events (TEAEs) Will be Summarized Using Frequency Counts. — 1; 3; 1; 2 Participants
N/A N=93 Hemodilution Validation of INVSENSOR00026
Healthy
Primary: Accuracy of Noninvasive Hemoglobin Sensor by Arms Calculation — 1.13 g/dL
N/A N=27 Burst Optimized Stimulation Study
Chronic Pain
Primary: Visual Analog Scale (VAS) for Pain — 46.88; 48.60; 46.76 units on a scale
N/A N=142 Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Change From Baseline to Week 4 in Meibomian Gland Score (MGS) — 17.3; 18.0; 17.7; 18.1 score on a scale
N/A N=1,493 A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON
Prostate Cancer
Primary: Incidence Rate of Adverse Events of Special Interest (AESI): Cardiovascular Events — 3.8; 4.5 Events per 100 PYE — p=0.4007
N/A N=119 The Effect of Two Different Tourniquet Techniques on Peripheral IV Access Success Rates
Tourniquet
Primary: Peripheral IV Access Success Rate — 42; 43 Participants — p=0.95
Phase 2 N=12 Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
Low-grade Glioma
Primary: Progression-free Survival — 23.1 percentage
N/A N=55 Type 2 Diabetes and Exercise Function in Single Leg Exercises
Type 2 Diabetes
Primary: Change in Muscle Oxygen Saturation — -10.7127; -8.9149; -12.471; -8.7883 percentage
N/A N=25 Tranexamic Acid and Blood Clots in Knee Surgery
Venous Thrombosis
Primary: Deep Vein Thrombosis — 2 Participants
Phase 4 N=135 Six Month Plaque and Gingivitis Study Using Colgate Total Toothpaste
Dental Plaque · Gingivitis
Primary: Dental Plaque Score — 3.53; 3.55; 3.59 units on a scale — p=0.919
Phase 2 N=46 A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure
Heart Failure · Decompensated Heart Failure · Acute Heart Failure
Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 5; 5; 7 Participants
Phase 4 N=154 Nitrofurantoin Prophylaxis During Catheter-managed Acute Urinary Retention After Pelvic Reconstructive Surgery
Pelvic Organ Prolapse
Primary: Number of Participants Experiencing Urinary Tract Infection Within 6 Weeks of Surgery — 13; 13 Participants — p=0.97
Phase 3 N=27 Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model
Caries
Primary: Percentage Surface Microhardness Recovery (%SMH) — 13.96; 30.59; 40.74; 48.28 Percent Surface Microhardness Recovery
N/A N=389 Special Investigation (Long-term Investigation) in Patients With Crohn's Disease
Crohn's Disease
Primary: Number of Participants With Adverse Events — 58; 104 participants